Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-08-06 20:18:03 ET · period of report 2026-08-04 · accession 0001865125-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-06 20:18 | 2026-08-04 | ELVN | Derynck Mika K | Dir | M - OptEx | $10.84 | +158.8K | 158.8K | New | +$1.72M |
| DT | 2026-08-06 20:18 | 2026-08-04 | ELVN | Derynck Mika K | Dir | S - Sale+OE | $60.21 | -158.8K | 0 | -100% | -$9.56M |
| DMT | 2026-08-06 20:18 | 2026-08-04 | ELVN | Derynck Mika K | Dir | M - OptEx | $0.00 | -158.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-04 | M | A | 87,373 | $2.48 | 87,373 | D | — | — | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
| 2 | Common | Common Stock | 2026-08-04 | M | A | 27,567 | $25.28 | 114,940 | D | — | — | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
| 3 | Common | Common Stock | 2026-08-04 | M | A | 23,364 | $14.85 | 138,304 | D | — | — | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
| 4 | Common | Common Stock | 2026-08-04 | M | A | 20,491 | $22.47 | 158,795 | D | — | — | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. |
| 5 | Common | Common Stock | 2026-08-04 | S | D | 158,795 | $60.21 | 0 | D | — | — | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 6 | Derivative | Stock Option (right to buy) | 2026-08-04 | M | D | 87,373 | $0.00 | 0 | D | $2.48 · — to 2031-08-01 | 87,373 Common Stock | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| 7 | Derivative | Stock Option (right to buy) | 2026-08-04 | M | D | 27,567 | $0.00 | 0 | D | $25.28 · — to 2033-02-23 | 27,567 Common Stock | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| 8 | Derivative | Stock Option (right to buy) | 2026-08-04 | M | D | 23,364 | $0.00 | 0 | D | $14.85 · — to 2034-02-13 | 23,364 Common Stock | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| 9 | Derivative | Stock Option (right to buy) | 2026-08-04 | M | D | 20,491 | $0.00 | 0 | D | $22.47 · — to 2035-02-06 | 20,491 Common Stock | (F1) The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |